Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-bridging and Broadening Study of Covaxin (BBV152) in Healthy Adults
NCT05258669Phase 3Unknown
- Sponsor
- Ocugen
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of COVAXIN in coronavirus disease 2019 (COVID-19), sponsored by Ocugen. Status: unknown.
02
Drugs
COVAXIN
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05258669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258669.